TBE/iStock Editorial via Getty Images
A federal court in Delaware reportedly ruled against Novartis (NYSE: NVS) is trying to block the launch of a generic version of its blockbuster drug Entresto.
Court rules on Novartis’ chances of winning on patent The infringement lawsuit against MSN Pharmaceuticals, the maker of a planned generic drug, is too low to prevent the product from entering the U.S. market. However, a court temporarily banned the product, while Novartis (NVSAn appeal was filed with the U.S. Court of Appeals for the Federal Circuit, Reuters reported.
The FDA approved MSN’s generic version of Entresto in July. Novartis (NVS) has been suing MSN and other drugmakers for patent infringement in an attempt to prevent generic versions of the heart failure drug from entering the market. Reuters added that the relevant patents will expire in 2026.
Entresto is Novartis’ (NVS) best-selling product, with 2023 sales of approximately $6 billion.
